TAE Life Sciences Secures $30M in Initial B Round Phase to Accelerate Development of Unique Boron Delivery Drugs for Novel Cancer Treatment
TAE Life Sciences Secures $30M in Initial B Round Phase to Accelerate Development of Unique Boron Delivery Drugs for Novel Cancer Treatment
06/02/20, 2:18 PM
Location
foothill ranchMoney raised
$30 million
TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company's initial funding in 2018.
Company Info
Location
foothill ranch, california, united states
Additional Info
At TAE Life Sciences, our mission is to advance Boron Neutron Capture Therapy (BNCT). Our foundational platform beam technology is derived from decades of development by TAE Technologies, Inc., an innovative leader in fusion energy technology. Leveraging their groundbreaking work for clinical investigation, TAE Life Sciences is developing the next generation of low-energy neutron beams – optimized for BNCT and practical for typical hospital settings. We have assembled a world-class, cross-functional team of clinicians, radiation oncologists, physicists, and other researchers to enable us to bring our technology to those who need it most.